Impact of Peritoneal Interposition Flap on Patients Undergoing Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis of Randomized Controlled Trials

May, Matthias; Gilfrich, Christian; Bründl, Johannes; Ubrig, Burkhard; Wagner, Joseph R.; Gloger, Simon; Študent, Vladimír; Merseburger, Axel S.; Thomas, Christian; Brookman‐May, Sabine; Wolff, Ingmar

doi:10.1016/j.euf.2023.07.007

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a systematic review comprising four RCTs (PIANOFORTE, PerFix, ProLy and PLUS) reported a significant risk reduction regarding sLC formation by performing intraoperative PIF [17]. Another recent meta-analysis included a fifth RCT, the PELYCAN trial, and found a reduction in postoperative LC formation but not in sLC formation [18].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Follow-Up of Peritoneal Interposition Flap in Symptomatic Lymphocele Reduction following Robot-Assisted Radical Prostatectomy: Insights from the PIANOFORTE Trial

Goßler,

May,

Weikert

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

The available randomised controlled trials (RCTs) assessing the influence of peritoneal interposition flaps (PIF) on the reduction of symptomatic lymphoceles (sLCs) post robot-assisted radical prostatectomy (RARP) do not constitute a sufficient follow-up (FU) to assess the long-term effects. The PIANOFORTE trial was the first of these RCTs, showing no sLC reduction at the 3-month FU. Therefore, all 232 patients from the PIANOFORTE trial were invited for long-term FU. One hundred seventy-six patients (76%) presented themselves for FU and constituted the study group (SG). The median FU duration was 43 months. No significant differences in group allocation or LC endpoints at 90 days were observed between SG patients and patients not presenting themselves for the FU. During the FU period, four patients (2.3%) in the SG developed sLCs, and six patients (3.4%) developed asymptomatic lymphoceles (aLCs), which persisted in five patients (2.9%). There were no significant differences between PIF and non-PIF regarding sLC/aLC formation or persistence, newly developed complications, stress urinary incontinence or biochemical/clinical tumour recurrence. Therefore, this long-term FU confirms the primary outcomes of the PIANOFORTE trial that, while PIF does not impact complications or functionality, it does not reduce sLC/aLC rates. Furthermore, it shows the potential occurrence of LC after the third postoperative month.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Modification of the RARP technique with PIF is generally considered a safe procedure [17,18]. With regard to other complications, such as chronic suprapubic pain or hernia, there were no statistically significant differences between the original study group and the control group at long-term follow-up.…”

Section: Discussionmentioning

confidence: 99%